|
CN101316583A
(zh)
|
2005-09-30 |
2008-12-03 |
生命医药公司 |
用特异性rxr激动剂治疗癌症
|
|
US8722710B2
(en)
|
2007-09-26 |
2014-05-13 |
Deuterx, Llc |
Deuterium-enriched pioglitazone
|
|
JP6014155B2
(ja)
|
2011-10-31 |
2016-10-25 |
ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． |
ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
|
|
US9630929B2
(en)
|
2011-10-31 |
2017-04-25 |
Xenon Pharmaceuticals Inc. |
Benzenesulfonamide compounds and their use as therapeutic agents
|
|
WO2013090616A1
(en)
|
2011-12-13 |
2013-06-20 |
Io Therapeutics, Inc. |
Autoimmune disorder treatment using rxr agonists
|
|
US10653650B2
(en)
|
2011-12-13 |
2020-05-19 |
Io Therapeutics, Inc. |
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
|
|
SG11201408284VA
(en)
*
|
2012-05-22 |
2015-02-27 |
Xenon Pharmaceuticals Inc |
N-substituted benzamides and their use in the treatment of pain
|
|
US10071957B2
(en)
|
2012-07-06 |
2018-09-11 |
Genentech, Inc. |
N-substituted benzamides and methods of use thereof
|
|
WO2014152843A1
(en)
|
2013-03-14 |
2014-09-25 |
Deuterx, Llc |
Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
|
|
US9550775B2
(en)
|
2013-03-14 |
2017-01-24 |
Genentech, Inc. |
Substituted triazolopyridines and methods of use thereof
|
|
MX2015010775A
(es)
|
2013-03-15 |
2016-04-25 |
Genentech Inc |
Benzoxazoles sustituidos y metodos para usarlos.
|
|
CR20160296A
(es)
|
2013-11-27 |
2016-09-20 |
Genentech Inc |
Benzamidas sustituidas y métodos para usarlas
|
|
EP3094328B1
(en)
|
2014-01-15 |
2020-08-19 |
Poxel SA |
Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
|
|
WO2015109318A2
(en)
*
|
2014-01-17 |
2015-07-23 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Therapeutic methods
|
|
WO2015187850A2
(en)
*
|
2014-06-03 |
2015-12-10 |
Duke University |
Compounds and methods for treatment of ocular disorders
|
|
CN106715418A
(zh)
|
2014-07-07 |
2017-05-24 |
基因泰克公司 |
治疗化合物及其使用方法
|
|
CN104490867A
(zh)
*
|
2014-12-03 |
2015-04-08 |
沈阳药科大学 |
苯甲酸衍生物在制备抗血管新生药物中的用途
|
|
WO2016153949A1
(en)
*
|
2015-03-20 |
2016-09-29 |
Deuterx, Llc |
5-deutero-thiazolidine-2,4-dione compounds and methods of treating medical disorders using same
|
|
JP2018520107A
(ja)
|
2015-05-22 |
2018-07-26 |
ジェネンテック， インコーポレイテッド |
置換ベンズアミド及びその使用方法
|
|
AU2016270373A1
(en)
|
2015-06-05 |
2018-01-04 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of demyelinating diseases
|
|
EP3341353A1
(en)
|
2015-08-27 |
2018-07-04 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
CN108290881B
(zh)
|
2015-09-28 |
2021-12-07 |
健泰科生物技术公司 |
治疗性化合物和其使用方法
|
|
CN116077626A
(zh)
|
2015-10-31 |
2023-05-09 |
Io治疗公司 |
使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
|
|
US10899732B2
(en)
|
2015-11-25 |
2021-01-26 |
Genentech, Inc. |
Substituted benzamides useful as sodium channel blockers
|
|
KR102605349B1
(ko)
|
2016-03-10 |
2023-11-22 |
아이오 테라퓨틱스, 인크. |
Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
|
|
US10835507B2
(en)
*
|
2016-03-10 |
2020-11-17 |
Io Therapeutics, Inc. |
Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
|
|
EP3854782A1
(en)
|
2016-03-30 |
2021-07-28 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
AU2017347549A1
(en)
|
2016-10-17 |
2019-05-02 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
WO2018106641A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Pyrazoles for the treatment of demyelinating diseases
|
|
WO2018106643A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic azoles for the treatment of demyelinating diseases
|
|
WO2018106646A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Aminotriazoles for the treatment of demyelinating diseases
|
|
US10238655B2
(en)
|
2017-01-23 |
2019-03-26 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Dihydroindene and tetrahydronaphthalene compounds
|
|
US10238626B2
(en)
|
2017-01-23 |
2019-03-26 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Therapeutic compounds
|
|
US10231947B2
(en)
|
2017-01-23 |
2019-03-19 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Isochroman compounds and methods of use thereof
|
|
CN108434116B
(zh)
*
|
2017-02-16 |
2021-05-11 |
人福普克药业（武汉）有限公司 |
贝萨罗汀软胶囊及其制备方法
|
|
JP2020511511A
(ja)
|
2017-03-24 |
2020-04-16 |
ジェネンテック， インコーポレイテッド |
ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
|
|
CA3076373A1
(en)
|
2017-09-20 |
2019-03-28 |
Io Therapeutics, Inc. |
Treatment of disease with esters of selective rxr agonists
|
|
AR114263A1
(es)
|
2018-02-26 |
2020-08-12 |
Genentech Inc |
Compuestos terapéuticos y métodos para utilizarlos
|
|
ES3025182T3
(en)
*
|
2018-03-01 |
2025-06-06 |
DJ Therapeutics LLC |
Bexarotene derivatives and their use in treating cancer
|
|
US11613517B2
(en)
|
2018-03-02 |
2023-03-28 |
Oregon Health & Science University |
Amide prodrugs of small molecule nuclear receptor modulators
|
|
WO2019191702A1
(en)
|
2018-03-30 |
2019-10-03 |
F. Hoffmann-La Roche Ag |
Substituted hydro-pyrido-azines as sodium channel inhibitors
|
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
CA3120970A1
(en)
|
2018-11-26 |
2020-06-04 |
Denali Therapeutics Inc. |
Methods for treating dysregulated lipid metabolism
|
|
AU2019397067A1
(en)
|
2018-12-12 |
2021-07-22 |
Autobahn Therapeutics, Inc. |
Novel thyromimetics
|
|
WO2020180624A1
(en)
|
2019-03-01 |
2020-09-10 |
Autobahn Therapeutics, Inc. |
Novel thyromimetics
|
|
US10966950B2
(en)
|
2019-06-11 |
2021-04-06 |
Io Therapeutics, Inc. |
Use of an RXR agonist in treating HER2+ cancers
|
|
US12466781B2
(en)
|
2019-11-29 |
2025-11-11 |
Autobahn Therapeutics, Inc. |
Thyromimetics
|
|
US12590072B2
(en)
|
2020-06-17 |
2026-03-31 |
Autobahn Therapeutics, Inc. |
Thyromimetics
|
|
WO2021257851A1
(en)
|
2020-06-17 |
2021-12-23 |
Autobahn Therapeutics, Inc. |
Thyromimetics
|
|
US11767317B1
(en)
|
2020-06-30 |
2023-09-26 |
Poxel Sa |
Methods of synthesizing enantiopure deuterium-enriched pioglitazone
|
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
|
CA3242047A1
(en)
|
2021-12-07 |
2023-06-15 |
Io Therapeutics, Inc. |
Use of an rxr agonist in treating drug resistant her2+ cancers
|
|
AU2022408160A1
(en)
|
2021-12-07 |
2024-06-06 |
Board Of Regents, The University Of Texas System |
Use of an rxr agonist and taxanes in treating her2+ cancers
|